Sanjay S. Shukla, M.D., M.S.

Sanjay S. Shukla, M.D., M.S. has served as our President and Chief Executive Officer and as a board member since November 2017. Dr. Shukla served as our Chief Medical Officer from March 2016 to November 2017. From April 2015 to March 2016, Dr. Shukla worked in an advisory capacity for a number of companies, including as a consultant to aTyr from January 2016 to March 2016. Prior to that, from October 2012 to April 2015, Dr. Shukla served as Vice President and Global Head of Integrated Medical Services for Novartis, a biopharmaceutical company, where he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. Dr. Shukla served as Chief Executive Officer of RXMD, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates, from April 2009 to September 2012. Prior to that, Dr. Shukla served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma, a biopharmaceutical company, and Aspreva Pharmaceuticals (acquired by Vifor Pharma). Dr. Shukla received his M.D. from Howard University College of Medicine and his Bachelors of Science in Microbiology and Master of Science in Epidemiology and Biostatistics from the University of Maryland.

Paul Schimmel, Ph.D.

Paul Schimmel, Ph.D. has served as a director since September 2005. Dr. Schimmel is currently a director of Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, as well as a director of several private companies. Dr. Schimmel is an Ernest and Jean Hahn Professor at The Skaggs Institute for Chemical Biology at The Scripps Research Institute. He was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology. Dr. Schimmel holds a B.A. in biochemistry and biophysics from Ohio Wesleyan University and a Ph.D. from the Massachusetts Institute of Technology.

Svetlana Lucas, Ph.D.

Dr. Svetlana Lucas has 18 years of experience in strategy, commercialization, and business development leadership, with a particular expertise in oncology and immunology. She currently serves as a Chief Business Officer at a newly formed biotechnology company. Prior to her current role, she served as Senior Vice President, Business Development at Tizona Therapeutics, Inc. (Tizona), a clinical stage immunotherapy company, where she was responsible for the company’s business development strategy and transactions, including global strategic collaboration with AbbVie Inc. Before joining Tizona, Dr. Lucas was Head of Oncology and Inflammation at Amgen Inc. (Amgen), where she oversaw business development activities, including Amgen’s strategic cancer immunotherapy research collaboration and licensing agreement with Kite Pharma, and collaborated with Amgen Ventures on several investments in oncology and inflammation. Dr. Lucas joined Amgen following the acquisition of Onyx Pharmaceuticals, Inc. (Onyx), where she spearheaded the company’s oncology partnering strategy and due diligence of new opportunities. Prior to Onyx, she held positions of increasing responsibility in strategy, business development and strategic marketing at Amgen, PDL BioPharma/Facet Biotech (acquired by AbbVie), and XOMA Corporation. She began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company, Inc. Dr. Lucas received her Ph.D. in Molecular Biology and Biochemistry from California Institute of Technology, and an undergraduate degree in Biology from Moscow State University.

Jane Gross, Ph.D.

Dr. Jane Gross is an accomplished executive with more than 28 years of experience leading research and development in the design and development of therapeutics for the treatment of autoimmune, inflammatory diseases and cancer. Dr. Gross has deep experience in research and development, partnering and alliance management of multiple internal and co-development programs. She currently serves as Chief Scientific Officer, Senior Vice President, Research and Development of Aptevo Therapeutics Inc. (Aptevo), a position she has held since September 2016. In this role, Dr. Gross led the discovery of novel protein therapeutics based on the ADAPTIR™ platform in immuno-oncology, leading research efforts in molecular biology and protein engineering, immunology, protein and cell sciences, pharmacology and translational research. Prior to joining Aptevo, Dr. Gross served as Vice President, Applied Research and Non-Clinical Development at Emergent BioSolutions Inc. and Vice President, Immunology Research at ZymoGenetics, Inc., where she led efforts in discovery and development of therapeutics from novel genes. Dr. Gross holds a Ph.D. in Immunology from the University of California, Berkeley under Jim Allison (2018 recipient of the Nobel Prize in Physiology and Medicine) and a Post-Doctoral Fellowship from the University of Washington in Immunology.

Nancy Denyes

Nancy Denyes has served as our General Counsel since February 2019 and as our Corporate Secretary since January 2015. Ms. Denyes served as our Vice President, Legal Affairs from October 2014 to February 2019. And provided consulting services to us from 2013 to 2014. Ms. Denyes practiced law in the corporate department at Cooley LLP and was named partner in 2000. Her practice at Cooley was focused on securities and corporate matters, including private financings, public offerings, mergers and acquisitions and corporate governance and disclosure issues. Ms. Denyes holds a J.D. from University of California, Berkeley School of Law and B.A. in Economics and Business from the University of California, Los Angeles.


Testing display of HTML elements – h1 tag

This is a test paragraph.

This is 2nd level heading – h2 tag

This is a test paragraph.

This is 3rd level heading – h3 tag

This is a test paragraph.

This is 3rd level heading – h3 tag with class .even

This is 3rd level heading – h3 tag with class .odd

This is 4th level heading – h4 tag

This is a test paragraph.

This is 5th level heading

This is a test paragraph.

This is 6th level heading

This is a test paragraph.

Basic block level elements

This is the caption for the image
This is the caption for the image

TOGETHER WE believe that MicroRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease.

This is a normal paragraph. To add some length to it, let us mention that this page was primarily written for testing the effect of user style sheets. You can use it for various other purposes as well, like just checking how your browser displays various HTML elements by default. It can also be useful when testing conversions from HTML format to other formats, since some elements can go wrong then. Dysregulated microRNA expression is a key factor in many complex multi-factoral diseases, including inflammatory disease, fibrosis, metabolic disease and cancer. microRNA therapeutics are oligonucleotides that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat a broad range human disease.This is another paragraph. I think it needs to be added that the set of elements tested is not exhaustive in any sense.

Balboa Park 1915 caption
Balboa Park 1915 caption

microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome. A single microRNA can target and regulate up to hundreds of genes and these genes are involved in biological networks or pathways.I have selected those elements for which it can make sense to write user style sheet rules, in my opinion.

Together, the Regulus team is leading the way in the discovery and development of microRNA therapeutics.

Regulus was formed in September 2007 by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals, now Ionis Pharmaceuticals (NASDAQ:IONS) and has continued to build upon our thought leadership, knowledge base, intellectual property and a clear focus to become the leader in microRNA therapeutics. The Regulus systems approach has mapped more than 6,000 diseases to specific tissue pathologies as well as their driver genes. It has linked specific microRNAs to the regulation of those driver genes and tissue disease states. Regulus has benefited from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. Regulus can access over 850 patents and patent applications in oligonucleotide technologies as well as owning over 200 patents and patent applications directed to microRNA delivery, manufacturing and specific technologies.

This is a block quotation containing a single paragraph. Well, not quite, since this is not really quoted text, but I hope you understand the point. After all, this page does not use HTML markup very normally anyway.

Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery, development and commercialization.


  • One.
  • Two.
  • Three. Well, probably this list item should be longer. Note that for short items lists look better if they are compactly presented, whereas for long items, it would be better to have more vertical spacing between items.
  • Four. This is the last item in this list. Let us terminate the list now without making any more fuss about it.

lorum ipsum text here to show odd

lorem upsum to show even

This is a paragraph before a numbered list (ol). Note that the spacing between a paragraph and a list before or after that is hard to tune in a user style sheet. You can””t guess which paragraphs are logically related to a list, e.g. as a “list header”.

  1. One.
  2. Two.
  3. Three. Well, probably this list item should be longer. Note that if items are short, lists look better if they are compactly presented, whereas for long items, it would be better to have more vertical spacing between items.
  4. Four. This is the last item in this list. Let us terminate the list now without making any more fuss about it.


This is a text paragraph that contains some inline links. Generally, inline links (as opposite to e.g. links lists) are problematic from the usability perspective, but they may have use as “incidental”, less relevant links. See the document Links Want To Be Links.



The following table has a caption. The first column contain table header cells (th elements) only; other cells are data cells with even/odd classes.

Sample table: Areas of the Nordic countries, in sq km
Country Total area Land area
Denmark 43,070 42,370
Finland 337,030 305,470
Iceland 103,000 100,250
Norway 324,220 307,860
Sweden 449,964 410,928
© 2007 - 2021   aTyr Pharma.   Legal   Privacy Policy